Abstract
Objective To determine whether the addition of a primary aldosteronism (PA) predictive model to a secondary hypertension decision support tool increases screening for PA in a primary care setting.
Materials and Methods 153 primary care clinics were randomized to receive a secondary hypertension decision support tool with or without an integrated predictive model between August 2023 and April 2024.
Results For patients with risk scores in the top 1 percentile, 63/2,896 (2.2%) patients where the alert was displayed in model clinics had the order set launched while 12/1,210 (1.0%) in no model clinics had the order set launched (P = 0.014). 19/2,896 (0.66%) of these highest risk patients in model clinics had an ARR ordered compared to 0/1,210 (0.0%) patients in no model clinics (P = 0.010). For patients with scores not in the top 1 percentile, 438/20,493 (2.1%) patients in model clinics had the order set launched compared to 273/17,820 (1.5%) in no model clinics (P < 0.001). 124/20,493 (0.61%) in model clinics had an ARR ordered compared to 34/17,820 (0.19%) in the no model clinics (P < 0.001).
Discussion The addition of a PA predictive model to secondary hypertension alert displays and triggering criteria along with order set displays and order preselection criteria results in a statistically and clinically significant increase in screening for PA, a condition that clinicians insufficiently screen for currently.
Conclusion Addition of a predictive model for an under-screened condition to traditional clinical decision support may increase screening for these conditions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Novant Health Institutional Review Board approval 22-2214
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Patient level data used in the study is not available as a waiver of informed consent was given by the institutional review board given the nature of clinical decision support studies.
